Acrivon Therapeutics, Inc. (ACRV) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 17, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 12, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ACRV SEC filings page.
This page shows Acrivon Therapeutics, Inc. (ACRV) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Acrivon remains a research-funded business: 2025 losses eased as spending fell, while a smaller balance sheet changed how liquidity was funded.
From FY2024 to FY2025, the net loss narrowed as R&D, SG&A, and operating cash outflow all decreased; with revenue unreported, the improvement is best read as spending control rather than demonstrated commercialization.
R&D and SG&A together totaled
Total assets fell from
Financial Health Signals
Acrivon Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Acrivon Therapeutics, Inc. passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Acrivon Therapeutics, Inc. reported a net loss of $77.9M while operations used $63.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Acrivon Therapeutics, Inc.'s EBITDA was -$18.3M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 18.3% from the same quarter a year earlier. Against the prior quarter it is up 6.4%.
Acrivon Therapeutics, Inc. reported -$18.0M in net income in Q2 2026. This represents an increase of 14.5% from the same quarter a year earlier. Against the prior quarter it is up 5.7%.
Acrivon Therapeutics, Inc. earned -$0.43 per diluted share (EPS) in Q2 2026. This represents an increase of 21.8% from the same quarter a year earlier. Against the prior quarter it is up 12.2%.
Not reported for Q2 2026.
Cash & Balance Sheet
Acrivon Therapeutics, Inc. recorded an outflow of $14.9M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 12.6% from the same quarter a year earlier. Against the prior quarter it is up 27.3%.
Acrivon Therapeutics, Inc. held $41.4M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Acrivon Therapeutics, Inc.'s ROE was -20.7% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 6.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.8 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Acrivon Therapeutics, Inc. invested $13.8M in research and development in Q2 2026. This represents a decrease of 14.4% from the same quarter a year earlier. Against the prior quarter it is down 8.7%.
Acrivon Therapeutics, Inc. invested $87K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 82.4% from the same quarter a year earlier. Against the prior quarter it is up 521.4%.
Not reported for Q2 2026.
ACRV Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $13.8M-14.4% | $15.2M-1.6% | N/A | $13.6M-27.7% | $16.2M+7.7% | $15.4M+34.4% | N/A | $18.9M+83.7% |
| SG&A Expenses | $4.8M-25.4% | $4.7M-24.2% | N/A | $6.0M-3.8% | $6.5M+0.9% | $6.2M+0.9% | N/A | $6.3M+6.9% |
| Operating Income | -$18.7M+17.6% | -$19.9M+8.1% | N/A | -$19.7M+21.7% | -$22.6M-5.7% | -$21.7M-22.6% | N/A | -$25.1M-55.8% |
| EBITDA | -$18.3M+18.3% | -$19.5M+8.6% | N/A | -$19.4M+22.0% | -$22.3M-5.2% | -$21.4M-22.4% | N/A | -$24.8M-54.9% |
| Net Income | -$18.0M+14.5% | -$19.0M+3.2% | N/A | -$18.2M+18.7% | -$21.0M-11.7% | -$19.7M-19.4% | N/A | -$22.4M-55.1% |
| EPS (Basic) | -$0.43+21.8% | -$0.49+3.9% | -$0.49+16.9% | -$0.47+20.3% | -$0.55-5.8% | -$0.51+30.1% | -$0.59+32.2% | -$0.59+10.6% |
| EPS (Diluted) | -$0.43+21.8% | -$0.49+3.9% | -$0.49+16.9% | -$0.47+20.3% | -$0.55-5.8% | -$0.51 | -$0.59+32.2% | -$0.59 |
| Diluted Shares (Avg) | 42M+8.8% | 39M+1.0% | N/A | 39M+1.2% | 38M+6.4% | 38M | N/A | 38M |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.
ACRV Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $99.1M-37.5% | $107.8M-38.9% | $129.7M-34.0% | $145.3M-32.3% | $158.6M-31.2% | $176.3M+46.3% | $196.6M+42.2% | $214.7M+42.1% |
| Current Assets | $91.5M-33.9% | $99.2M-34.4% | $120.4M-33.7% | $130.4M-31.0% | $138.4M-24.1% | $151.3M+34.9% | $181.6M+40.0% | $189.0M+30.8% |
| Cash & Equivalents | $41.4M-1.1% | $34.1M-13.0% | $41.5M+4.2% | $35.4M-18.4% | $41.9M-8.9% | $39.2M+59.1% | $39.8M+10.6% | $43.4M+45.4% |
| Short-Term Investments | $48.5M-49.2% | $63.7M-42.4% | $77.1M-44.8% | $93.8M-34.8% | $95.5M-29.0% | $110.5M+29.4% | $139.7M+52.7% | $144.0M+28.3% |
| Long-Term Investments | $0-100.0% | $0-100.0% | $0-100.0% | $5.1M-66.8% | $10.2M-74.4% | $15.2M | $5.1M | $15.4M |
| Total Liabilities | $12.4M-20.1% | $12.3M-22.8% | $17.2M-13.1% | $16.7M-6.2% | $15.5M+7.0% | $16.0M+27.2% | $19.8M+16.0% | $17.8M+37.5% |
| Current Liabilities | $11.4M-14.8% | $11.1M-18.4% | $15.7M-9.0% | $14.9M+0.5% | $13.4M+19.0% | $13.6M+49.9% | $17.2M+29.4% | $14.8M+59.4% |
| Non-Current Liabilities | $980K-53.7% | $1.3M-47.6% | $1.5M-40.6% | $1.8M-39.3% | $2.1M-34.8% | $2.4M-31.2% | $2.6M-31.3% | $3.0M-18.4% |
| Total Equity | $86.7M-39.4% | $95.5M-40.4% | $112.5M-36.4% | $128.6M-34.7% | $143.0M-33.8% | $160.4M+48.5% | $176.8M+45.9% | $196.9M+42.5% |
| Retained Earnings | -$311.9M-31.2% | -$293.9M-35.7% | -$274.9M-39.6% | -$255.9M-46.9% | -$237.7M-56.7% | -$216.7M-63.0% | -$197.0M-69.2% | -$174.1M-79.2% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
ACRV Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$14.9M+10.5% | -$20.5M-5.1% | -$15.2M+12.2% | -$12.3M+29.1% | -$16.6M-19.5% | -$19.5M-14.4% | -$17.4M-40.4% | -$17.3M-76.7% |
| Depreciation & Amortization | $400K+33.3% | $383K+23.2% | $361K+19.1% | $300K0.0% | $300K+50.0% | $311K+38.8% | $303K+103.4% | $300K+200.0% |
| Stock-Based Compensation | $2.2M-43.6% | $2.2M-42.5% | N/A | $3.9M+6.5% | $3.9M+10.1% | $3.8M+13.4% | N/A | $3.7M+13.7% |
| Capital Expenditures | $87K-82.4% | $14K-75.9% | $219K-73.5% | $899K-9.1% | $493K+259.9% | $58K-92.9% | $827K-28.1% | $989K |
| Free Cash Flow | -$14.9M+12.6% | -$20.6M-4.9% | -$15.5M+15.0% | -$13.2M+28.0% | -$17.1M-21.8% | -$19.6M-9.5% | -$18.2M-34.5% | -$18.3M-86.7% |
| Investing Cash Flow | $14.9M-23.2% | $13.1M-31.7% | $21.5M+49.3% | $5.9M-63.1% | $19.5M+122.1% | $19.2M+228.4% | $14.4M-29.8% | $16.0M+956.1% |
| Financing Cash Flow | $7.3M+7593.8% | -$33K+90.4% | -$192K+70.3% | -$117K+92.2% | -$97K-100.1% | -$343K-99.4% | -$647K+67.8% | -$1.5M-2028.2% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
ACRV Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -20.7%-6.0pp | -19.9%-7.7pp | N/A | -14.2%-2.8pp | -14.7%-6.0pp | -12.3%+3.0pp | N/A | -11.4%-0.9pp |
| Return on Assets | -18.1%-4.9pp | -17.7%-6.5pp | N/A | -12.6%-2.1pp | -13.3%-5.1pp | -11.2%+2.5pp | N/A | -10.4%-0.9pp |
| Current Ratio | 7.99-2.3x | 8.98-2.2x | 7.69-2.9x | 8.75-4.0x | 10.31-5.9x | 11.17-1.2x | 10.55+0.8x | 12.75-2.8x |
| Debt-to-Equity | 0.140.0x | 0.130.0x | 0.150.0x | 0.130.0x | 0.110.0x | 0.100.0x | 0.110.0x | 0.090.0x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Acrivon Therapeutics, Inc. ACRV | FY2025 | N/A | -$77.9M | N/A | $70.3M | — |
| Tempest Therapeutics, Inc. TPST | FY2025 | N/A | -$26.3M | N/A | $10.5M | — |
| Radiopharm Theranostics Limited RADX | FY2025 | $3.6M | -$38.3M | N/A | $15.0M | 20/100 |
| PLUS THERAPEUTICS, Inc. PSTV | FY2025 | $5.2M | -$22.4M | N/A | $26.6M | 32/100 |
| Telomir Pharmaceuticals, Inc. TELO | FY2025 | N/A | -$10.4M | N/A | $77.3M | — |
| Lunai Bioworks Inc. RENB | FY2025 | N/A | N/A | N/A | $46.3M | — |
Where Acrivon Therapeutics, Inc. Ranks
Frequently Asked Questions
Is Acrivon Therapeutics, Inc. profitable?
No, Acrivon Therapeutics, Inc. (ACRV) reported a net income of -$77.9M in fiscal year 2025.
What is Acrivon Therapeutics, Inc.'s EBITDA?
Acrivon Therapeutics, Inc. (ACRV) had EBITDA of -$82.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Acrivon Therapeutics, Inc.'s return on equity (ROE)?
Acrivon Therapeutics, Inc. (ACRV) has a return on equity of -69.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Acrivon Therapeutics, Inc.'s free cash flow?
Acrivon Therapeutics, Inc. (ACRV) recorded an outflow of $65.3M in free cash flow during fiscal year 2025. This represents a 4.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Acrivon Therapeutics, Inc.'s operating cash flow?
Acrivon Therapeutics, Inc. (ACRV) recorded an outflow of $63.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Acrivon Therapeutics, Inc.'s total assets?
Acrivon Therapeutics, Inc. (ACRV) had $129.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Acrivon Therapeutics, Inc.'s capital expenditures?
Acrivon Therapeutics, Inc. (ACRV) invested $1.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Acrivon Therapeutics, Inc. spend on research and development?
Acrivon Therapeutics, Inc. (ACRV) invested $60.0M in research and development during fiscal year 2025.
What is Acrivon Therapeutics, Inc.'s current ratio?
Acrivon Therapeutics, Inc. (ACRV) had a current ratio of 7.69 as of fiscal year 2025, which is generally considered healthy.
What is Acrivon Therapeutics, Inc.'s debt-to-equity ratio?
Acrivon Therapeutics, Inc. (ACRV) had a debt-to-equity ratio of 0.15 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Acrivon Therapeutics, Inc.'s return on assets (ROA)?
Acrivon Therapeutics, Inc. (ACRV) had a return on assets of -60.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Acrivon Therapeutics, Inc.'s P/E ratio?
Acrivon Therapeutics, Inc. (ACRV) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $70.3M as of Oct 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Acrivon Therapeutics, Inc.'s price-to-sales ratio?
Acrivon Therapeutics, Inc. (ACRV) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $70.3M as of Oct 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Acrivon Therapeutics, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Acrivon Therapeutics, Inc. (ACRV) held $118.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $63.7M over that year. Dividing the one by the other, the reported balance equals about 22 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Acrivon Therapeutics, Inc.'s Piotroski F-Score?
Acrivon Therapeutics, Inc. (ACRV) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Acrivon Therapeutics, Inc.'s earnings high quality?
Acrivon Therapeutics, Inc. (ACRV) reported a net loss of $77.9M while operations used $63.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.